Inicio > Medicina > Enfermería y servicios auxiliares > Servicios de primeros auxilios y de auxiliares sanitarios > Deriving Drug Discovery Value from Large-Scale Genetic Bioresources
Deriving Drug Discovery Value from Large-Scale Genetic Bioresources

Deriving Drug Discovery Value from Large-Scale Genetic Bioresources

AA.VV

41,08 €
IVA incluido
Disponible
Editorial:
National Academies Press
Año de edición:
2016
Materia
Servicios de primeros auxilios y de auxiliares sanitarios
ISBN:
9780309447782
41,08 €
IVA incluido
Disponible

Selecciona una librería:

  • Librería Samer Atenea
  • Librería Aciertas (Toledo)
  • Kálamo Books
  • Librería Perelló (Valencia)
  • Librería Elías (Asturias)
  • Donde los libros
  • Librería Kolima (Madrid)
  • Librería Proteo (Málaga)
Sobre IBD

The process of discovering and developing a new drug or therapy is extremely costly and time consuming, and recently, it has been estimated that the creation of a new medicine costs on average more than $2 billion and takes 10 years to reach patients. The challenges associated with bringing new medicines to market have led many pharmaceutical companies to seek out innovative methods for streamlining their drug discovery research.One way to increase the odds of success for compounds in the drug development pipeline is to adopt genetically guided strategies for drug discovery, and recognizing the potential benefits of collecting genetic and phenotypic information across specific populations, pharmaceutical companies have started collaborating with healthcare systems and private companies that have curated genetic bioresources, or large databases of genomic information. Large-scale cohort studies offer an effective way to collect and store information that can be used to assess gene–environment interactions, identify new potential drug targets, understand the role of certain genetic variants in the drug response, and further elucidate the underlying mechanisms of disease onset and progression.To examine how genetic bioresources could be used to improve drug discovery and target validation, the National Academies of Sciences, Engineering, and Medicine hosted a workshop in March 2016. Participants at the workshop explored the current landscape of genomics-enabled drug discovery activities in industry, academia, and government; examined enabling partnerships and business models; and considered gaps and best practices for collecting population data for the purpose of improving the drug discovery process. This publication summarizes the presentations and discussions from the workshop.

Artículos relacionados

  • Primeros auxilios. MF0272.
    Olga Martín Villaoslada
    Puede solicitar gratuitamente las soluciones a todas las actividades en el email tutor@tutorformacion.esCapacidades que se adquieren con este Manual:- Identificar las características de la asistencia como primer interviniente.- Aplicar técnicas de valoración inicial según el protocolo establecido accediendo al accidentado de forma oportuna y generando un entorno seguro.- Aplica...
    Disponible

    32,19 €

  • Direct-to-Consumer Genetic Testing
    Today, scores of companies, primarily in the United States and Europe, are offering whole genome scanning services directly to the public. The proliferation of these companies and the services they offer demonstrate a public appetite for this information and where the future of genetics may be headed; they also demonstrate the need for serious discussion about the regulatory en...
    Disponible

    35,31 €

  • Incorporating Occupational Information in Electronic Health Records
    Each year in the United States, more than 4,000 occupational fatalities and more than 3 million occupational injuries occur along with more than 160,000 cases of occupational illnesses. Incorporating patients’ occupational information into electronic health records (EHRs) could lead to more informed clinical diagnosis and treatment plans as well as more effective policies, inte...
    Disponible

    31,72 €

  • Cognitive Rehabilitation Therapy for Traumatic Brain Injury
    Traumatic brain injury (TBI) may affect 10 million people worldwide. It is considered the ’signature wound’ of the conflicts in Iraq and Afghanistan. These injuries result from a bump or blow to the head, or from external forces that cause the brain to move within the head, such as whiplash or exposure to blasts. TBI can cause an array of physical and mental health concerns and...
    Disponible

    58,19 €

  • Health IT and Patient Safety
    IOM’s 1999 landmark study To Err is Human estimated that between 44,000 and 98,000 lives are lost every year due to medical errors. This call to action has led to a number of efforts to reduce errors and provide safe and effective health care. Information technology (IT) has been identified as a way to enhance the safety and effectiveness of care. In an effort to catalyze its i...
    Disponible

    43,63 €

  • A Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials
    The nanotechnology sector, which generated about $225 billion in product sales in 2009, is predicted to expand rapidly over the next decade with the development of new technologies that have new capabilities. The increasing production and use of engineered nanomaterials (ENMs) may lead to greater exposures of workers, consumers, and the environment, and the unique scale-specifi...
    Disponible

    51,48 €